- Home
- HRMY vs EVT Comparison
HRMY vs EVT Comparison
Compare HRMY & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | EVT |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | EVT |
|---|---|---|
| Price | $37.06 | $26.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $49.75 | N/A |
| AVG Volume (30 Days) | ★ 612.6K | 115.5K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.32% |
| EPS Growth | ★ 50.44 | N/A |
| EPS | 3.17 | ★ 6.63 |
| Revenue | ★ $825,944,000.00 | $69,404,302.00 |
| Revenue This Year | $23.34 | N/A |
| Revenue Next Year | $16.28 | N/A |
| P/E Ratio | $11.49 | ★ $3.55 |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $19.20 |
| 52 Week High | $40.87 | $25.83 |
Technical Indicators
Market Signals| Indicator | HRMY | EVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 64.53 |
| Support Level | $36.27 | $25.82 |
| Resistance Level | $38.04 | $26.33 |
| Average True Range (ATR) | 1.18 | 0.28 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 50.14 | 93.89 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.